ClinicalTrials.gg
CompletedNCT03332667Updated Apr 16, 2025Results posted

MIBG With Dinutuximab +/- Vorinostat

A Phase 1 interventional study of 131I-MIBG and Dinutuximab in Neuroblastoma, sponsored by New Approaches to Neuroblastoma Therapy Consortium. Completed at 12 sites in United States. Open to participants aged 1 Year to 30 Years. Per ClinicalTrials.gov, last updated 2025-04-16.

Sponsored by New Approaches to Neuroblastoma Therapy Consortium · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
1 Year to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing dinutuximab in Neuroblastoma — 9 open to participants now, 14 under way, 4 of them phase 3. dinutuximab · Neuroblastoma.

Enrollment
11th of 27
45 · median 35
Started
2018
the only one that year
Phase 1
8 of 27
1 open now
Registered
14th of 27
by date
Lead sponsor
4 of 27
New Approaches to Neuroblastoma Therapy Consortium

Among the 27 studies testing dinutuximab in Neuroblastoma, this one is the 11th largest by enrollment, is the only one that started in 2018, is one of 8 in phase 1, and was the 14th registered.

Neuroblastoma

676 studies on the registry are indexed under Neuroblastoma; 128 are open to participants now.

Browse Neuroblastoma studies →

Open to participants now

9 of the 27 studies testing dinutuximab in Neuroblastoma are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About dinutuximab

dinutuximab: first FDA approval 2015 (UNITUXIN), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 105 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 75 (71%) stop at 75 or younger; 102 take children under 18; 3 take healthy volunteers.

This study: 1 Year to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing dinutuximab in Neuroblastoma, or all of them as a file.
02

Study summary

131I-Metaiodobenzylguanidine (131I-MIBG) is one of the most effective therapies utilized for neuroblastoma patients with refractory or relapsed disease. In this pediatric phase 1 trial, 131I-MIBG will be given in combination with dinutuximab, a chimeric 14.18 monoclonal antibody. This study will utilize a traditional Phase I rolling 6 dose escalation design to determine a recommended phase 2 pediatric dose. An expansion cohort of an additional 6 patients will then be enrolled. If tolerable, vorinostat will then be added to the third dose level. A 6 patient expansion cohort may then be enrolled.

Read the detailed description

131I-Metaiodobenzylguanidine (131I-MIBG) is one of the most effective therapies utilized for neuroblastoma patients with refractory or relapsed disease. Data from pre-clinical and adult studies suggest that radiation can enhance the efficacy of immunotherapy and targeted therapies such as dinutuximab. This first pediatric phase 1 trial of 131I-MIBG in combination with dinutuximab and vorinostat aims to determine the recommended phase 2 pediatric dose of these three therapies in combination.

03

Conditions studied

  • Neuroblastoma

Browse trials for

04

Who can participate

Ages eligible
1 Year to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must have evidence of MIBG uptake into tumor at ≥ 1 site (bone or soft tissue) within 28 days prior to study entry and subsequent to any intervening therapy.
  2. Patients must have a diagnosis of neuroblastoma either by histologic verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines.
  3. Patients must have a history of high-risk neuroblastoma according to COG risk classification at the time of study registration. Patients who were initially considered low or intermediate-risk, but then reclassified as high-risk are also eligible.
  4. All patients must have at least one of the following

    1. Recurrent/progressive disease: after the diagnosis of high risk neuroblastoma at any time prior to enrollment regardless of response to frontline therapy
    2. No prior history of recurrent/progressive disease since the diagnosis of high risk neuroblastoma b1) disease- a best overall response of no response/stable disease since diagnosis of high risk neuroblastoma and at least 4 cycles of induction therapy. No prior history of recurrent/progressive disease since the diagnosis of high risk neuroblastoma.

      b2) Persistent disease- a best overall response of no partial response since diagnosis of high risk neuroblastoma and at least 4 cycles of induction therapy. No prior history of recurrent/progressive disease since the diagnosis of high risk neuroblastoma.

  5. Patients must have at least ONE of the following (lesions may have received prior radiation therapy as long as they meet the other criteria listed below):

    a) For recurrent/progressive or refractory disease, at least one MIBG avid bone site.

    b) For persistent disease, if a patient has 3 or more MIBG avid lesions, then no is required. If a patients has only 1 or 2 MIBG avid bone lesion sites then biopsy confirmation of neuroblastoma or ganglioneuroblastoma in at least one MIBG avid site present at the time of enrollment is required to be obtained at any time point prior to enrollment.

    c) For MIBG non-avid tumors, patients must have at least one FDG avid site and a biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma at any time prior to enrollment from at least one FDG-avid site.

  6. Any amount of neuroblastoma tumor cells in the bone marrow done at the time of study enrollment based on routine morphology with or without immunocytochemistry in at least one sample from bilateral aspirates and biopsies.
  7. At least one soft tissue lesion that meets criteria for a TARGET lesion as defined by:

    a) SIZE: Lesion can be accurately measured in at least one dimension with a longest diameter ≥ 10 mm, or for lymph nodes ≥ 15 mm on short axis. Lesions meeting size criteria will be considered measurable.

    b) In addition to size, a lesion needs to meet one of the following criteria except for patients with parenchymal CNS lesions which only need to meet size criteria: b1) MIBG avid. For patients with recurrent/progressive or refractory disease, no biopsy is required. For patients with persistent disease only: If a patient has only 1 or 2 MIBG avid lesions sites, then biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma in at least one MIBG avid site present at time of enrollment is required to be obtained. If a patient has 3 or more MIBG avid lesions, then no biopsy is required.

    b2) MIBG non avid tumors: Patients must have at least one FDG avid site and biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma in at least one FDG-PET avid site present at the time of enrollment.

  8. At least one non-target soft tissue lesion that is not measurable, but had a biopsy positive for neuroblastoma and/or ganglioneuroblastoma or is MIBG avid at any time prior to enrollment.
  9. Patients must have a of at least 12 weeks and a Lansky (≤16 years) or (>16 years) score of at least 50.
  10. Prior Therapy 1. Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to study registration.
  1. Patients must not have received the therapies indicated below after disease evaluation or within the specified time period prior to registration on this study as follows:
  1. Myelosuppressive chemotherapy: must not have received within 2 weeks prior to registration.
  1. Biologic anti-neoplastics- agents not known to be associated with reduced or ANC counts (including retinoids): must not have received within 7 days prior to registration.
  1. Monoclonal antibodies: must have received last dose at least 7 days or 3 half-lives whichever is longer, but no longer than 30 days (with recovery of any associated toxicities), prior to protocol therapy.
  1. Cellular Therapy (e.g. modified T cells, NK cells, dentritic cells etc.): must not have received within 3 weeks and resolution of all toxicities.
  1. Radiation: must not have received small port radiation within 7 days prior to registration.
  1. Hematopoietic Stem Cell Transplant: 7. IVIG 8. Therapeutic MIBG 9. medicines covered under another IND 10. Medications interfering with MIBG uptake 11. Medications that prolong (Part B only) 12. Valproic acid (Part B only) 11) All patients must have adequate organ function defined as:
  • Hematological Function:
  1. Absolute Phagocyte count (APC= neutrophils and monocytes): ≥ 1000/µL
  2. : ≥750/µL
  3. Absolute Lymphocyte count ≥ 500/µL
  4. Platelet count: ≥ 50,000/µL, transfusion independent (no platelet transfusions within 1 week)
  5. ≥ 10 g/dL (may transfuse)
  6. Patients with known bone marrow disease will be eligible for study as long as they meet hematologic function criteria above.

    • Renal Function: Age-adjusted serum creatinine ≤ to 1.5 x normal for age/gender OR or greater than or equal to 60 cc/min/1.73m2
    • Liver Function: Total ≤ 1.5 x normal for age, AND (ALT) 135 and SGOT (AST) ≤ 3 x . Sinusoidal obstruction syndrome (SOS) if present, must be stable or improving clinically
    • Cardiac Function: Normal documented by either echocardiogram or radionuclide MUGA evaluation OR Normal fractional shortening documented by echocardiogram
    • Pulmonary Function: No dyspnea at rest, no oxygen requirement.

      1. Reproductive Status: All post-menarchal females must have a negative beta-HCG. Males and females of reproductive age and must use effective for the duration of their participation.
      1. Patients with other ongoing serious medical issues must be approved by the study chair prior to registration.
      1. Autologous peripheral blood stem cells (PBSC)•The minimum dose for peripheral blood stem cells is 2.0 x 106viable CD34+ cells/kg. Patients who do not meet this minimum requirement for available PBSCs are not eligible. •Only un-purged stem cells are allowed unless a center has separate FDA approval for infusion of purged stem cells. •For patients whose body weight exceeds ideal body weight (IBW) by more than 20%, adjusted body weight may be used for the calculation of PBSC dose 15) Physician deems that there is reasonable ability to obtain vorinostat via commercial supply (Part B Only)

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, breast feeding, or unwillingness to use effective during the study.
  • Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
  • Patients with disease of any major organ system that would compromise their ability to withstand therapy.
  • Patients who have received prior stem cell transplant
  • Patients who have received prior solid organ transplantation
  • Patients must not have received prior total body irradiation
  • Prior HDAC inhibitor given in combination with therapeutic 131I-MIBG(Part B only)
  • The maximum total allowable dose of 131I-MIBG that can be given per institutional guidelines must be at least 90% of the calculated 131I-MIBG dose or the patient is not eligible.
  • Patients who are on hemodialysis.
  • Patients with an active or uncontrolled infection.
  • Known history of (HIV) infection, , or .
  • Patient declines participation in NANT 2004-05, the NANT Biology Study
  • Patients and/or families who are physically and psychologically unable to cooperate with the radiation safety isolation.
  • Patients with a history of having to discontinue anti-GD2 antibody therapy due to toxicity are not eligible.
  • Prior anti-GD2 therapy is not otherwise an exclusionary criteria unless it was given in combination with therapeutic 131I-MIBG.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Cohort A DL1

    Patients will receive 131I-MIBG on day 1 at 12 mCi/kg/dose. Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy at 17.5 mg/m2/dose. Patient will receive GM-CSF on days 8-17 and 29-38 at 250 mcg/m2. All patients will receive autologous hematopoietic stem cell infusion on day 15 (+/- 2) of therapy

    Radiation: 131I-MIBG · Drug: Dinutuximab · Drug: Sargramostim · Drug: Potassium Iodide

  • Experimental
    Cohort A DL2

    Patients will receive 131I-MIBG on day 1 at 15 mCi/kg/dose. Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy at 17.5 mg/m2/dose. Patient will receive GM-CSF on days 8-17 and 29-38 at 250 mcg/m2. All patients will receive autologous hematopoietic stem cell infusion on day 15 (+/- 2) of therapy

    Radiation: 131I-MIBG · Drug: Dinutuximab · Drug: Sargramostim · Drug: Potassium Iodide

  • Experimental
    Cohort A DL3

    Patients will receive 131I-MIBG on day 1 at 18 mCi/kg/dose. Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy at 17.5 mg/m2/dose. Patient will receive GM-CSF on days 8-17 and 29-38 at 250 mcg/m2. All patients will receive autologous hematopoietic stem cell infusion on day 15 (+/- 2) of therapy

    Radiation: 131I-MIBG · Drug: Dinutuximab · Drug: Sargramostim · Drug: Potassium Iodide

  • Experimental
    Cohort B DL4

    Vorinostat will be given on days 0-13 at 180 mg/m2/dose. Patients will receive 131I-MIBG on day 1 at 18 mCi/kg/dose. Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy at 17.5 mg/m2/dose. Patient will receive GM-CSF on days 8-17 and 29-38 at 250 mcg/m2. All patients will receive autologous hematopoietic stem cell infusion on day 15 (+/- 2) of therapy

    Radiation: 131I-MIBG · Drug: Dinutuximab · Drug: Vorinostat · Drug: Sargramostim · Drug: Potassium Iodide

Interventions

  • Radiation131I-MIBG

    Patients will receive 131I-MIBG on day 1. 131I-MIBG dose will be based on the dose level assigned at the time of patient registration

    Also known as: 131I-Metaiodobenzylguanidine, Iobenguane sulfate, m-Iodobenzylguanidine sulfate, MIBG

  • Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab dose will be based on the dose level assigned at the time of patient registration.

    Also known as: Chimeric Monoclonal Antibody 14.18, MAB Ch 14.18, Unituxin, Ch14.18

  • Vorinostat will be given on day 0-13. Vorinostat dose will be based on the dose level assigned at the time of patient registration.

    Also known as: Zolina

  • Sargramostim (GM-CSF) will be given on day 8-17 at 250 mcg/m\^2

  • Potassium iodide will be given by mouth at a dose of 6mg/kg 8-12 hours prior to infusion of 131I-MIBG on Day 1 and then 1mg/kg/dose by mouth starting 4-6 hours after completion of MIBG infusion and continuing every 4 hours on protocol days 1-7 and then 1mg/kg/dose by mouth once daily on protocol days 8-45

06

What researchers measure

Primary outcomes

  1. MTD/RP2D Determination Cohort A

    Proportion of patients with Course 1 DLT in Cohort A

    Time frame: All toxicities from enrollment until completion of course 1 (Day 56)

  2. MTD/RP2D Determination Cohort B

    Proportion of patients with Course 1 DLT in Cohort B

    Time frame: All toxicities from enrollment until completion of course 1 (Day 56)

  3. Describe Non-Hematological Toxicities Cohort A

    Proportion of patients with any grade 3 or greater non-hematological toxicities in Cohort A

    Time frame: All toxicities from enrollment through 30 days following end of protocol therapy, up to 5 months

  4. Describe Non Hematological Toxicities Cohort B

    Proportion of patients with any grade 3 or greater non-hematological toxicities in Cohort B

    Time frame: All toxicities from enrollment through 30 days following end of protocol therapy, up to 5 months

Secondary outcomes

  1. Overall Response Cohort A

    Proportion of patients evaluable for response with a best overall response of CR/CR-MD/PR for patients in Cohort A

    Time frame: From Day 1 of protocol therapy through 30 days following end of protocol therapy, up to 5 months

  2. Overall Response Cohort B

    Proportion of patients evaluable for response with a best overall response of CR/CR-MD/PR for patients in Cohort B

    Time frame: From Day 1 of protocol therapy through 30 days following end of protocol therapy, up to 5 months

07

Results

Posted Apr 16, 2025

Participant flow

Participant flow — Overall Study
MilestoneCohort A DL1Cohort A DL2Cohort A DL3Cohort B DL4
Started652014
Completed12611
Not completed53143
Withdrew: Adverse event0021
Withdrew: Withdrawal by subject2151
Withdrew: Disease progression or relapse2130
Withdrew: Initiation onto another anti-cancer therapy1131
Withdrew: No treatment received0010

Outcome measures

PrimaryMTD/RP2D Determination Cohort A

Proportion of patients with Course 1 DLT in Cohort A

Time frame:
All toxicities from enrollment until completion of course 1 (Day 56)
Reported as:
Count of participants · Participants
MTD/RP2D Determination Cohort A
ParticipantsCohort A DL1Cohort A DL2Cohort A DL3
MTD/RP2D Determination Cohort A000
PrimaryMTD/RP2D Determination Cohort B

Proportion of patients with Course 1 DLT in Cohort B

Time frame:
All toxicities from enrollment until completion of course 1 (Day 56)
Reported as:
Count of participants · Participants
MTD/RP2D Determination Cohort B
ParticipantsCohort B DL4
MTD/RP2D Determination Cohort B1
PrimaryDescribe Non-Hematological Toxicities Cohort A

Proportion of patients with any grade 3 or greater non-hematological toxicities in Cohort A

Time frame:
All toxicities from enrollment through 30 days following end of protocol therapy, up to 5 months
Reported as:
Count of participants · Participants
Describe Non-Hematological Toxicities Cohort A
ParticipantsCohort A DL1Cohort A DL2Cohort A DL3
Describe Non-Hematological Toxicities Cohort A5310
PrimaryDescribe Non Hematological Toxicities Cohort B

Proportion of patients with any grade 3 or greater non-hematological toxicities in Cohort B

Time frame:
All toxicities from enrollment through 30 days following end of protocol therapy, up to 5 months
Reported as:
Count of participants · Participants
Describe Non Hematological Toxicities Cohort B
ParticipantsCohort B DL4
Describe Non Hematological Toxicities Cohort B12
SecondaryOverall Response Cohort A

Proportion of patients evaluable for response with a best overall response of CR/CR-MD/PR for patients in Cohort A

Time frame:
From Day 1 of protocol therapy through 30 days following end of protocol therapy, up to 5 months
Reported as:
Count of participants · Participants
Overall Response Cohort A
ParticipantsCohort A DL1Cohort A DL2Cohort A DL3
Overall Response Cohort A245
SecondaryOverall Response Cohort B

Proportion of patients evaluable for response with a best overall response of CR/CR-MD/PR for patients in Cohort B

Time frame:
From Day 1 of protocol therapy through 30 days following end of protocol therapy, up to 5 months
Reported as:
Count of participants · Participants
Overall Response Cohort B
ParticipantsCohort B DL4
Overall Response Cohort B5

Adverse events

Collected over All adverse events from enrollment through 30 days following end of protocol therapy, up to 5 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A DL14/6 (66.7%)3/6 (50%)6/6 (100%)
Cohort A DL21/5 (20%)2/5 (40%)5/5 (100%)
Cohort A DL312/20 (60%)6/20 (30%)19/20 (95%)
Cohort B DL45/14 (35.7%)8/14 (57.1%)14/14 (100%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventCohort A DL1Cohort A DL2Cohort A DL3Cohort B DL4
DehydrationMetabolism and nutrition disorders0/61/50/204/14
FeverGeneral disorders0/61/50/202/14
Urinary tract painRenal and urinary disorders0/61/50/200/14
Jejunal obstructionGastrointestinal disorders1/60/50/200/14
Platelet count decreasedInvestigations1/60/50/200/14
Tumor painNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/60/50/201/14
Spinal cord compressionNervous system disorders1/60/50/200/14
Urinary retentionRenal and urinary disorders1/60/50/200/14
Abdominal painGastrointestinal disorders0/60/50/202/14
Febrile neutropeniaBlood and lymphatic system disorders0/60/50/201/14
Most frequent other events
Showing 10 of 150
Most frequent other events
EventCohort A DL1Cohort A DL2Cohort A DL3Cohort B DL4
AnemiaBlood and lymphatic system disorders6/64/516/2012/14
VomitingGastrointestinal disorders3/65/510/2012/14
Lymphocyte count decreasedInvestigations6/65/516/2014/14
Platelet count decreasedInvestigations5/65/516/2013/14
White blood cell decreasedInvestigations6/65/518/2013/14
HypoalbuminemiaMetabolism and nutrition disorders5/65/513/2012/14
Neutrophil count decreasedInvestigations5/63/515/2013/14
NauseaGastrointestinal disorders3/62/514/2012/14
HypocalcemiaMetabolism and nutrition disorders5/64/510/2012/14
Sinus tachycardiaCardiac disorders5/62/59/207/14

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort A DL1Cohort A DL2Cohort A DL3Cohort B DL4Total
<=18 years55191140
Between 18 and 65 years10135
>=65 years00000
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A DL1Cohort A DL2Cohort A DL3Cohort B DL4Total
Female227718
Male4313727
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort A DL1Cohort A DL2Cohort A DL3Cohort B DL4Total
Hispanic or Latino13318
Not Hispanic or Latino42141333
Unknown or Not Reported10304
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A DL1Cohort A DL2Cohort A DL3Cohort B DL4Total
American Indian or Alaska Native00112
Asian00011
Native Hawaiian or Other Pacific Islander00000
Black or African American00325
White5312929
More than one race00011
Unknown or Not Reported12407
08

Study locations

12 sites
  • Children's Hospital Los Angeles
    Los Angeles, California 90027-0700, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco, California 94143, United States
  • Children Hospital of Colorado
    Aurora, Colorado 80045, United States
  • AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus
    Atlanta, Georgia 30322, United States
  • University of Chicago, Comer Children's Hospital
    Chicago, Illinois 60637, United States
  • Children's Hospital Boston
    Boston, Massachusetts 02115, United States
  • C.S Mott Children's Hospital
    Ann Arbor, Michigan 48109, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27599, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229-3039, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104-4318, United States
  • Cook Children's Healthcare System
    Fort Worth, Texas 76104, United States
  • Children's Hospital and Regional Medical Center - Seattle
    Seattle, Washington 98105, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Feb 2024, 65 months.

Results were first posted in Apr 2025, 1 year 1 month after primary completion.

Of 73 non-industry phase 1 interventional studies under Neuroblastoma, half reached primary completion within 89 months of starting (the median), counting those still running; a quarter within 65 and three quarters within 117. This study's 65 months is below that.

Counting every sponsor, half of 86 studies reached it within 83 months; a quarter within 60 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2017
First posted
Nov 6, 2017
StartActual
Sep 12, 2018
Primary completionActual
Feb 23, 2024
CompletionActual
Feb 23, 2024
Results first posted
Apr 16, 2025
Last update
Apr 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03332667
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Sep 12, 2018
Primary completion
Feb 23, 2024
Completion
Feb 23, 2024
Results posted
Apr 16, 2025
Last update
Apr 16, 2025

Study contacts

Thomas Cash, MD
study chair · Children's Healthcare of Atlanta
Araz Marachelian, MD, MS
study director · Children's Hospital Los Angeles

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dinutuximab

Start the discussion